Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{207376,
        author = {Yashasvi Saxena and Dr Pranay Kumar Singh and Dr Sumit Bhateja and Dr Vineeta Charan},
        title = {Biochemical Markers Of Oral Cancer},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {3},
        pages = {642-648},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=207376},
        abstract = {Early identification of oral squamous cell carcinoma (OSCC) is critical to improving patient outcomes, since early management correlates with clinical survival rates of over 85%. The carcinogenic cascade, which is fueled by major etiologies like tobacco use, chronic alcohol consumption, and human papillomavirus (HPV-16) infection, is primarily propelled by enhanced reactive oxygen species (ROS) and consequent lipid peroxidation. Traditional reactive techniques, which rely mainly on invasive tissue biopsies, are being replaced by proactive, multifluid molecular surveillance approaches. This research presents a highly authentic multi-omic framework for bridging the gap between benchtop molecular discoveries and point-of-care clinical diagnostics.
Methodologically, this comprehensive approach uses high-throughput salivary proteomics via Ultra-Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) and Luminex multiplex assays to evaluate a core proteomic signature that includes matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), and chemerin, with diagnostic sensitivity of up to 94%. Concurrently, transcriptome surveillance using reverse transcription-quantitative PCR (RT-qPCR) identifies a high-fidelity seven-marker mRNA signature, including DUSP1 and OAZ1, that detects subclinical malignant changes before they become macroscopically visible. Serum glycomics uses advanced spectrophotometric analysis to offer precise quantifications of Total Sialic Acid (TSA) and Lipid-Bound Sialic Acid (LBSA) for real-time monitoring of systemic tumor load and clinical staging (TNM stages I–IV). Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) and exosomal microRNAs (miR-21, miR-184) allows for non-invasive deep genomic profiling and real-time tracking of occult primary tumors and therapeutic resistance. Finally, immunohistochemical (IHC) validation of tissue architecture using p53, Ki-67, and glucose transporter-1 (GLUT-1) confirms cellular proliferation indexes and the aggr. Combining these clinical pillars into a single multi-marker diagnostic panel significantly decreases false-positive "noise" from localized inflammatory conditions like as periodontitis, maximizing both sensitivity and specificity. Finally, switching from isolated single-marker testing to integrated multi-omic scores creates a comprehensive, high-resolution biochemical protocol that alters the paradigm of modern oral oncology from reactive clinical monitoring to precise, ultra-early treatment intercept.},
        keywords = {Oral Squamous Cell Carcinoma (OSCC) , Liquid Biopsy ,Salivary Proteomics , Multi-Omic Integration , Serum Glycomics ,Transcriptomic Signature , Matrix Metalloproteinase-9 (MMP-9) , Sialic Acid , Warburg Effect , Circulating Tumor DNA (ctDNA) ,  Point-of-Care Diagnostics},
        month = {August},
        }